pyrroles has been researched along with Dyslipidemia in 236 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 80 (33.90) | 29.6817 |
| 2010's | 150 (63.56) | 24.3611 |
| 2020's | 6 (2.54) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, A; Ishii, I; Kamata, S; Machida, Y; Nemoto, A; Oyama, T; Satta, C; Terasawa, K; Uchii, K | 1 |
| Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A | 1 |
| Chhina, RS; Goyal, O; Goyal, P | 1 |
| Alonso, C; Bedossa, P; Bhat, M; Caffrey, R; Giri, SR; Jain, MR; Koduru, SV; Kumar, DP; Marioneaux, J; Philip, B; Santhekadur, PK; Sanyal, AJ | 1 |
| Faldu, K; Krishnappa, M; Maroo, S; Mody, N; Parmar, D; Parmar, K; Patil, K; Shah, C; Trivedi, P | 1 |
| Chhina, RS; Goyal, O; Goyal, P; Kaur, J; Nohria, S; Sharma, S; Sood, A | 1 |
| Cheng, XC; Feng, XY; Jia, WQ; Jing, Z; Liu, JW; Liu, X; Liu, YY; Wang, SQ; Xu, WR | 1 |
| Giri, P; Gupta, L; Jain, MR; Modi, N; Patel, H; Patel, P; Patel, U; Shah, K; Singh, S; Srinivas, NR | 1 |
| Shah, SN | 1 |
| Bhagat, A; Bhosle, D; Bhosle, V; Bobde, J; Kadam, R; Shaikh, H | 1 |
| Balakumar, P; Mahadevan, N; Sambathkumar, R | 1 |
| Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S | 1 |
| Jaiswal, A; Kaul, U; Manjunath, K; Parmar, D; Parmar, K; Patil, KP; Shah, M | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Borrego, L; Hernández, N; Peñate, Y | 1 |
| Gupta, YK; Padhy, BM; Yadav, R | 1 |
| Ghannouchi, MM; Hamdi, W; Kaffel, D; Kchir, MM | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 1 |
| Goto, SN; Mizuno, Y; Niwa, M; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW | 1 |
| Adamson, U; Jörneskog, G; Lins, PE; Mobarrez, F; Tehrani, S; Wallén, HN | 1 |
| Ivanovic, B; Tadic, M | 1 |
| Agrawal, R | 1 |
| Kikuchi, M; McCrary Sisk, C; Nakagomi, M; Numaguchi, H; Shirakawa, M; Surks, HK; Tamura, S; Teramoto, T | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 2 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Almeida, S; Bruxel, EM; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Van der Sand, CR; Van der Sand, LC | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Abdallah, FR; Aldohmy, S; Elseweidy, MM; Kassem, HM; Younis, NN | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ | 1 |
| Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF | 1 |
| Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C | 1 |
| Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T | 1 |
| David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK | 1 |
| Gong, HR; Huang, WY; Li, XP; Zhao, SP | 1 |
| Campese, VM | 1 |
| Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Cho, EJ; Kim, JH; Sutradhar, S; Westergaard, M; Yunis, C | 1 |
| Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA | 1 |
| Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Marrett, E; Neff, DR; Ramey, DR; Tershakovec, AM; Tomassini, JE; Zhang, NJ; Zhang, Q; Zhao, C | 1 |
| Al-Azzam, SI; Alzayadeen, RN; Alzoubi, KH; Khabour, OF | 1 |
| Grzegorzewska, AE; Jagodziński, PP; Janków, M; Niepolski, L; Sikora, J; Sowińska, A | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B | 1 |
| Boland, BS; Chang, JT; Sandborn, WJ | 1 |
| Sun, B; Yan, WJ; Zhang, WL; Zou, ZP | 1 |
| Akagi, H; Akasaka, T; Imanishi, T; Ino, Y; Kitabata, H; Komukai, K; Kubo, T; Kumiko, H; Matsuo, Y; Okumoto, Y; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Takarada, S; Tanaka, A; Tanimoto, T; Ueno, S; Yamaguchi, T; Yamano, T | 1 |
| Basile, G; Catalano, A; Cucinotta, D; Lasco, A; Morabito, N | 1 |
| Huang, C; Li, Z; Liu, H; Song, X; Wang, X | 1 |
| Chen, Y; Fan, Y; Jiang, C; Liu, F; Liu, M | 1 |
| Joshi, SR | 1 |
| Barter, PJ; Brewer, HB; Ford, J; Hovingh, GK; Kastelein, JJ; Rader, DJ; Round, P; Saleheen, D; van Deventer, SJ | 1 |
| Ray, KK; Vallejo-Vaz, AJ | 1 |
| Mearns, BM | 1 |
| Crea, F; Niccoli, G | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Luthra, A; Misra, A | 2 |
| Mudur, G | 1 |
| Hokimoto, S; Kaikita, K; Ogawa, H; Shimomura, H; Sugiyama, S; Tsujita, K; Yamanaga, K | 4 |
| Koh, KK | 1 |
| Goldstein, MR; Mascitelli, L | 1 |
| Jain, M; Jani, RH | 1 |
| Chandurkar, N; Pareek, A | 1 |
| Lloyd-Jones, D; Smith, S; Stone, NJ | 1 |
| Chapman, J; Giral, P; Hansel, B | 1 |
| Bedogni, F; Montone, RA; Testa, L | 1 |
| Abdel-Wahab, M; Richardt, G | 1 |
| Ahlehoff, O; Egeberg, A; Hansen, PR; Qureshi, AA; Robertson, D; Strober, BE; Tan, H; Valdez, H; Wolk, R; Wu, JJ | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Watts, GF | 1 |
| Nambi, V; Polsani, VR; Virani, SS | 1 |
| Derdemezis, C; Elisaf, M; Filippatos, T; Mikhailidis, D; Tselepis, A | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Ginsberg, HN; Ramakrishnan, R | 1 |
| Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF | 1 |
| Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S | 1 |
| Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA | 1 |
| Arihiro, K; Chayama, K; Hyogo, H; Inoue, M; Ishitobi, T; Iwamoto, K; Nabeshima, Y; Nonaka, M; Tazuma, S | 1 |
| Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ | 1 |
| Barbik-Zhagar, B; Belenkov, IuN; Mareev, VIu; Oganov, RG | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Bestermann, WH; Dyess, EM; Graff, A; Kursun, A; Neutel, JM; Sutradhar, S; Yunis, C | 1 |
| Bloomfield, D; Carlson, GL; Littlejohn, TW; McKenney, JM; Mitchel, Y; Pasternak, RC; Sapre, A; Sisk, CM; Tribble, D | 1 |
| Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Davidson, MH; Fayyad, RS; Koren, MJ; Reed, DP; Wilson, DJ; Zuckerman, A | 1 |
| Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C | 1 |
| Hsia, J; Otvos, JD; Rosenson, RS | 1 |
| Daferera, N; Goulas, A; Hatzitolios, AI; Kokkas, V; Kosmidou, M; Molyva, D; Raikos, N; Savopoulos, C | 1 |
| Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M | 1 |
| Tokgözoğlu, L | 1 |
| Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD | 1 |
| Bangalore, S; Devabhaktuni, M | 1 |
| Hoskova, L; Kautzner, J; Kubanek, M; Malek, I; Podzimkova, M; Skalicka, B; Vymetalova, Y | 1 |
| Knopp, RH; Krieger, EV | 1 |
| Das, R; Jaydip, R; Mohan, V; Sudhakaran, C; Unnikrishnan, R | 1 |
| Longyhore, DS; Stockton, CM; Thomas, MR | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Day, A; Kumar, SS; LaHaye, SA; Lahey, KA | 1 |
| Curran, MP | 1 |
| Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW | 1 |
| Arihiro, K; Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Nabeshima, Y; Takeuchi, M; Yamagishi, S | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Alvaro, D; Attili, AF; Bragazzi, MC; Callea, F; Giubilo, F; Merli, M | 1 |
| Ahn, TH; Ahn, YK; Bae, JH; Baek, SH; Choi, DJ; Choi, YJ; Hong, SJ; Hong, TJ; Hur, SH; Ihm, SH; Jang, YS; Kim, BS; Kim, DI; Kim, HS; Kim, YJ; Lee, CW; Lee, SH; Lee, SU; Park, DG; Ryu, KH; Seung, KB | 1 |
| Harinarayan, CV; Kumar, R; Pola, P; Rajagopal, G; Reddy, AP; Sachan, A; Suchitra, MM; Suresh, V | 1 |
| Grimm, R; Kursun, A; Malik, M; Sutradhar, S; Yunis, C | 1 |
| Fujimori, S; Kaneko, K; Ogata, N; Oka, Y | 1 |
| Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K | 1 |
| Adamson, U; Antovic, A; Henriksson, P; Jörneskog, G; Lins, PE; Mobarrez, F; Santesson, P; Tehrani, S; Wallén, NH | 1 |
| Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL | 1 |
| Lopatin, IuM | 1 |
| Colivicchi, F; Santini, M; Tubaro, M | 1 |
| Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA | 1 |
| Aksoy, N; Bas, M; Buyukhatıpoglu, H; Celik, H; Demirbag, R; Guntekin, U; Polat, M; Sezen, Y; Taskin, A; Yildiz, A | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Bastien, NR; Francis, GA; Genest, JJ; Goodman, SG; Langer, A; Leiter, LA; McPherson, R | 1 |
| Aleksandrowicz, E; Larczyński, W; Lysiak-Szydłowska, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Ziętkiewicz, M | 1 |
| Mareev, VIu | 1 |
| Sasaki, J | 1 |
| Wilke, RA | 1 |
| Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Betteridge, J | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Amano, T; Aoyama, T; Hayashi, M; Ishii, H; Matsubara, T; Murohara, T; Nishio, M; Takahashi, H; Tamaki, T; Tanaka, M; Toriyama, T; Yoshikawa, D | 1 |
| Abolhasani, E; Araghi, ZM; Beiraghdar, F; Panahi, Y; Pishgoo, B; Sahebkar, A | 1 |
| Kelly, MT; Mohiuddin, SM; Setze, CM; Thakker, KM | 1 |
| Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K | 1 |
| Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotidou, A; Panagiotou, A; Polyzos, SA; Selalmatzidou, D; Slavakis, A | 1 |
| Kongsuwan, S; Niyomrat, P; Poolsup, N; Rungkanchananon, B; Suksomboon, N; Wongyaowarat, K | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Boh, M; Ceska, R; Jezovnik, M; Opolski, G; Poredos, P | 1 |
| Chen, ZY; Lei, L; Li, LY; Liu, Q; Liu, SN; Shen, ZF; Zhang, N | 1 |
| Bays, HE; Choi, YJ; Karpf, DB; Kerzner, B; Krauss, RM; Littlejohn, T; Naim, S; Roberts, BK; Schwartz, S; Wang, X | 1 |
| Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
| Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S | 1 |
| Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N | 1 |
| Shinohara, Y | 1 |
| Eussen, SR; Klungel, OH; Rompelberg, CJ; van Eijkeren, JC | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Teramoto, T | 1 |
| Chapman, MJ | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Bielecka, A; Bułdak, Ł; Duława-Bułdak, A; Krysiak, R; Madej, A; Okopień, B; Łabuzek, K | 1 |
| Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Maeda, S; Yamagishi, S | 1 |
| McKenney, JM | 1 |
| Bandgar, TR; Faruqui, AA | 1 |
| Jiang, P; Padley, RJ; Thakker, KM; Toth, PP | 1 |
| Ciesla-Dul, M; Undas, A; Zolcinski, M | 1 |
| Lonardo, A; Loria, P | 1 |
| Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP | 1 |
| Filippatos, TD | 1 |
| Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J | 1 |
| Alver, A; Calapoglu, M; Kural, B; Orem, A; Orem, C; Uydu, HA; Yıldırmış, S | 1 |
| Ban, MR; Hegele, RA; Rahalkar, AR | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Yamagishi, S | 1 |
| Doğru, MT; Ebinç, H; Sahin, O; Simşek, V; Tireli, E; Tulmac, M; Yildirim, N | 1 |
| Angelico, F; Del Ben, M; Pignatelli, P; Violi, F | 1 |
| Babazono, T; Fujimoto, A; Imamoto, M; Kasahara, M; Kimura, G; Koya, D; Nakao, K; Sato, T; Tanaka, S; Ueshima, K; Yasuno, S | 1 |
| Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A | 1 |
| Chung, JY; Lee, SH; Oh, ES; Park, K; Park, MS | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
| Jackevicius, CA; Krumholz, HM; Tu, JV | 1 |
| Adámková, V; Ceška, R; Dlouhá, D; Hubáček, JA; Lánská, V; Prusíková, M; Rynekrová, J; Vrablík, M; Zlatohlávek, L | 1 |
| Hyogo, H; Maeda, S; Yamagishi, S | 1 |
| Delgado-Montero, A; Zamorano, JL | 1 |
| Adámkova, V; Ceska, R; Dlouha, D; Hubacek, JA; Lanska, V; Vrablik, M | 1 |
| Arazi, SS; Bernik, MM; Bertolami, M; Brion, MJ; Carracedo, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC; Sobrino, B; Willrich, MA | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Sasaki, J; Uchida, Y | 1 |
| Dubas, K; Kersnik, J; Kijowska, V; Seifert, B; Tomasik, T; Windak, A | 1 |
| Artamoshina, NE; Belaya, OL; Bondar, KY; Kuropteva, ZV; Lazutina, OM; Raider, LM; Yakovleva, TV | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K | 1 |
| Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A | 1 |
| Alver, A; Kural, BV; Orem, A; Orem, C; Uydu, HA | 1 |
| Angelin, B; Asztalos, BF; Björkhem, I; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Rudling, M; Schaefer, EJ; Welty, FK; Wolfe, ML | 1 |
| Toth, PP | 1 |
| Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S | 1 |
| Bays, HE; McGovern, ME | 1 |
| Davidson, M | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Hobbs, FD | 1 |
| Davidson, MH | 1 |
| Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M | 1 |
| Bayés, B; Bonet, J; Granada, ML; Lauzurica, R; Llopis, MA; Navarro, M; Pastor, MC; Romero, R | 1 |
| Borges, JL | 1 |
| Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Zareba, G | 1 |
| Blank, R | 1 |
| García-Buey, L; Gisbert, JP; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R | 1 |
| Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Chu, CH; Chuang, MJ; Keng, HM; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Tai, MH; Wang, MC; Wei, MC | 1 |
| Belazi, D; Dickson, M; Meissner, B; Reeder, CE; Senevirante, V; Shinogle, J | 1 |
| Delliaux, S; Jammes, Y; Lesavre, N; Oliver, C; Paganelli, F; Steinberg, JG | 1 |
| Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W | 1 |
| Fitchett, DH; Goodman, SG; Langer, A; Leiter, LA | 1 |
| Healy, H; Morgan, C; Saltissi, D; Westhuyzen, J | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Ferrer-García, JC; Herrera-Ballester, A; Martínez-Mir, I; Pérez-Silvestre, J | 1 |
| Deshpande, S; Lokhandwala, Y | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Gupta, S; Hughes, EA; Lie, F; Patel, JV | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC; van der Steeg, WA | 1 |
| Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Chadarevian, R; Danchin, N; Gayet, JL; Licour, M; Valensi, P | 1 |
| Vos, E | 1 |
| Lachaine, J; Merikle, E; Montpetit, M; Rinfret, S; Tarride, JE | 1 |
| Claeys, M; Commers, K; Deforce, J; Ducobu, J; Nachtergaele, H; Van Mieghem, W; Vandenbroucke, M | 1 |
| Buranakitjaroen, P; Deerochanawong, C; Kosachunhanun, N; Nitiyanant, W; Piamsomboon, C; Sukonthasarn, A; Suwantamee, J; Suwanwela, NC; Vongthavaravat, V | 1 |
| Athyros, V; Farsang, C; Gaw, A | 1 |
| Bots, ML; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; Tegeler, CH; Vicari, RM; Visseren, FL | 1 |
| Lindberg, MB; Ohman, KP; Ose, L; Retterstøl, K; Svensson, M; Tonstad, S | 1 |
| Bolognese, MA; Bone, HG; Kiel, DP; Leary, ET; Lewiecki, EM; Lindsay, RS; Lowe, W; McClung, MR | 1 |
| Benatar, JR; Stewart, RA | 1 |
| Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F | 1 |
| Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ | 1 |
| McKeage, K; Siddiqui, MA | 1 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Farmer, JA; Jones, PH | 1 |
32 review(s) available for pyrroles and Dyslipidemia
| Article | Year |
|---|---|
A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2019 |
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; India; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction; Time Factors; Treatment Outcome | 2019 |
Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.
Topics: Atorvastatin; Biomarkers; Chi-Square Distribution; Down-Regulation; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Update on Janus kinase antagonists in inflammatory bowel disease.
Topics: Animals; Dyslipidemias; Humans; Inflammatory Bowel Diseases; Janus Kinases; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Topics: Animals; Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Lipids; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Risk Factors | 2015 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
[Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure].
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2009 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome | 2009 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Patient Compliance; Pyrroles; Treatment Outcome | 2010 |
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Neurology; Physicians; Pioglitazone; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrroles; Secondary Prevention; Stroke; Tetrazoles; Thiazolidinediones; Tissue Plasminogen Activator | 2010 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Flushing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Niacin; Pyrroles | 2012 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2005 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2006 |
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Risk Factors | 2005 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles; Tablets | 2006 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Death, Sudden, Cardiac; Dyslipidemias; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Stroke | 2006 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States | 2005 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2008 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
96 trial(s) available for pyrroles and Dyslipidemia
| Article | Year |
|---|---|
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Phenylpropionates; Pioglitazone; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2020 |
Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
Topics: Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Phenylpropionates; Prediabetic State; Prospective Studies; Pyrroles; Triglycerides | 2018 |
Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; India; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome | 2013 |
Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.
Topics: Administration, Cutaneous; Adult; Atorvastatin; Biomarkers; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pyrroles; Risk Factors; Skin; Sweden; Time Factors; Treatment Outcome; Vasodilator Agents | 2013 |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Oxazolidinones; Patient Safety; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2013 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Topics: Adult; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2014 |
[The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Latin America; Male; Middle Aged; Middle East; Preventive Health Services; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2014 |
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Tomography, Optical Coherence | 2014 |
Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women.
Topics: Administration, Oral; Atorvastatin; Bone Diseases, Metabolic; Calcifediol; Cholecalciferol; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Middle Aged; Postmenopause; Pyrroles; Vitamin D; Vitamin D Deficiency; Vitamins | 2015 |
[Efficacy and safety comparison of different statins in elderly patients].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Denmark; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Cross-Over Studies; Double-Blind Method; Down-Regulation; Dyslipidemias; Fenofibrate; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Models, Biological; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pilot Projects; Pyrroles | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome | 2009 |
Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycemic Index; Heptanoic Acids; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Pyrroles | 2008 |
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebos; Pyrroles | 2009 |
[Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Research Design; Risk Factors; Safety; Time Factors; Treatment Outcome; Triglycerides | 2008 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Life Style; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2009 |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxazolidinones; Pyrroles; Treatment Outcome | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2009 |
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Health Maintenance Organizations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2009 |
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2010 |
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Placebos; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides; White People | 2009 |
Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tablets; Time Factors; Treatment Outcome; Triglycerides; United States | 2009 |
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Biopsy; Body Mass Index; Dyslipidemias; Fatty Liver; Female; Follow-Up Studies; Glucose Tolerance Test; Glycation End Products, Advanced; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Reactive Oxygen Species; Tomography, X-Ray Computed; Young Adult | 2010 |
A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Topics: Adult; Aged; Algorithms; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Epidemiologic Research Design; Female; Heptanoic Acids; Humans; Interleukin-6; Korea; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Young Adult | 2010 |
Efficacy of low dose atorvastatin in diabetic dyslipidaemia.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tablets; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2010 |
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; France; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation | 2010 |
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Platelets; C-Reactive Protein; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Dyslipidemias; Fibrin; Fibrinolytic Agents; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta3; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Pyrroles; Sweden; Thrombin; Thromboplastin; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Topics: Adult; Atorvastatin; Cross-Over Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Pyrroles; Renal Insufficiency, Chronic | 2010 |
[Atorvastatin in the treatment of high risk patients with ischemic heart disease and dyslipidemia. Safety assessment in the Russian Multicenter Study ATLANTIKA].
Topics: Acute Coronary Syndrome; Aged; Aspartate Aminotransferases; Atorvastatin; Comparative Effectiveness Research; Drug Dosage Calculations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Networks and Pathways; Middle Aged; Monitoring, Physiologic; Pyrroles; Risk Assessment; Russia; Secondary Prevention; Treatment Outcome | 2010 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Dose-Response Relationship, Drug; Dyslipidemias; Female; Femoral Artery; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Results of a randomized,open-label,clinical trial investigating the effects of supplementation with Heracleumpersicum extract as an adjunctive therapy for dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Body Mass Index; Cholesterol; Dietary Supplements; Dyslipidemias; Female; Heptanoic Acids; Heracleum; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plant Extracts; Pyrroles | 2011 |
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2011 |
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
Topics: Adipokines; Aged; Atorvastatin; Blood Glucose; Cholesterol; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk.
Topics: Atorvastatin; Biomarkers; Blood Pressure; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Czech Republic; Double-Blind Method; Drugs, Generic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Poland; Pyrroles; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2011 |
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver; Male; Middle Aged; Overweight; PPAR delta; Pyrroles; Treatment Outcome | 2011 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Blood Pressure; Cholesterol; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 2011 |
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult | 2011 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Topics: Atorvastatin; Biomarkers; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; United States | 2012 |
Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Time Factors; Treatment Outcome; Triglycerides | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Single high dose atorvastatin does not ameliorate endothelial function and large arterial stiffness in dyslipidemic patients without atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Dyslipidemias; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Vascular Stiffness; Vasodilation | 2012 |
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Data Interpretation, Statistical; Disease Progression; Dyslipidemias; Endpoint Determination; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Research Design; Treatment Outcome | 2013 |
Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers.
Topics: Adult; Asian People; Atorvastatin; Biomarkers; Cholesterol, LDL; Computer Simulation; Decision Support Techniques; Down-Regulation; Drug Administration Schedule; Drug Dosage Calculations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Biological; Pyrroles; Republic of Korea; Treatment Outcome; Young Adult | 2012 |
Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study.
Topics: Adult; Atorvastatin; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Female; Glucose; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postmenopause; Pravastatin; Pyrroles; Young Adult | 2013 |
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Bile Acids and Salts; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Feces; Glycoproteins; Heptanoic Acids; Humans; Pyrroles; Quinolines; Sterols | 2005 |
Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Topics: Adiponectin; Adult; Atorvastatin; Biomarkers; Blood Glucose; C-Reactive Protein; Dyslipidemias; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney Transplantation; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Tumor Necrosis Factor-alpha | 2005 |
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Cross-Over Studies; Delayed-Action Preparations; Drug Carriers; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pyrroles; Reference Values; Simvastatin; Treatment Outcome | 2006 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss | 2006 |
The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyslipidemias; Endothelin-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2006 |
Effect of long-term atorvastatin treatment on the electrophysiological and mechanical functions of muscle.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dyslipidemias; Electromyography; Exercise; Female; Heptanoic Acids; Humans; Male; Middle Aged; Muscle Contraction; Muscle Fatigue; Muscle, Skeletal; Pyrroles; Triglycerides | 2006 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Pyrroles; Renal Dialysis; Triglycerides | 2006 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Spain | 2006 |
Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study.
Topics: Asia; Asian People; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Selection; Pilot Projects; Pyrroles; Treatment Outcome; United Kingdom | 2005 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles | 2007 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2007 |
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Quinolines; Tunica Intima | 2007 |
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Topics: Adult; Alkanesulfonates; Anticholesteremic Agents; Atorvastatin; Chemotherapy, Adjuvant; Cross-Over Studies; Drug Combinations; Drug Synergism; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Phenylpropionates; Pioglitazone; Placebos; PPAR alpha; PPAR gamma; Pyrroles; Thiazolidinediones | 2007 |
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Topics: Absorptiometry, Photon; Adult; Aged; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Middle Aged; Postmenopause; Pyrroles; Spine | 2007 |
Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cohort Studies; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Proteinuria; Pyrroles; Transforming Growth Factor beta | 2007 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles; Treatment Outcome | 2007 |
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Treatment Outcome | 2008 |
108 other study(ies) available for pyrroles and Dyslipidemia
| Article | Year |
|---|---|
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Topics: Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Domains; Pyrroles; Recombinant Proteins | 2021 |
Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.
Topics: Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2023 |
Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.
Topics: Diabetes Mellitus; Dyslipidemias; Elasticity Imaging Techniques; Humans; Liver; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles; Transaminases | 2020 |
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Endoplasmic Reticulum Stress; Gene Expression Profiling; Insulin Resistance; Liver; Liver Cirrhosis; Metabolomics; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction | 2020 |
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Prospective Studies; Pyrroles; Regression Analysis | 2020 |
Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar.
Topics: Diabetes Mellitus; Drug Discovery; Dyslipidemias; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Molecular Dynamics Simulation; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2018 |
Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
Topics: Animals; Caco-2 Cells; Dogs; Drug Evaluation, Preclinical; Dyslipidemias; Humans; Mice; Microsomes, Liver; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats | 2018 |
The Road to Preventing Diabetes: Addressing Prediabetes and Concomitant Dyslipidemia.
Topics: Diabetes Mellitus; Dyslipidemias; Humans; Phenylpropionates; Prediabetic State; Pyrroles | 2018 |
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2018 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Generalized erythematous-violaceous plaques in a patient with a history of dyslipidemia. Interstitial granulomatous drug reaction (IGDR).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Eruptions; Dyslipidemias; Erythema; Female; Granuloma; Heptanoic Acids; Humans; Pyrroles | 2013 |
Piriformis muscle syndrome: an unusual adverse effect of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Female; Heptanoic Acids; Humans; Magnetic Resonance Imaging; Middle Aged; Piriformis Muscle Syndrome; Pyrroles | 2013 |
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Drug Synergism; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Pyrroles; Risk Factors | 2013 |
The first approved agent in the Glitazar's Class: Saroglitazar.
Topics: Administration, Oral; Adult; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; India; Lipid Metabolism; Middle Aged; Phenylpropionates; Pyrroles; Young Adult | 2014 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Anticholesteremic Agents; Atorvastatin; Constitutive Androstane Receptor; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; PPAR alpha; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Retinoid X Receptor alpha; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits.
Topics: Animals; Atorvastatin; C-Reactive Protein; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Atherogenic; Disease Models, Animal; Dyslipidemias; Guaiacol; Heptanoic Acids; Inflammation; Male; Mass Spectrometry; Oxygen; Pyrroles; Rabbits; Risk Factors | 2013 |
HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Incidence; Indoles; Kidney Transplantation; Male; Middle Aged; Pyrroles; Renal Insufficiency | 2014 |
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Topics: Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States | 2014 |
The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gene-Environment Interaction; Genotype; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Receptors, Leptin; Sex Factors; Triglycerides | 2014 |
Effect of lifestyle changes and atorvastatin administration on dyslipidemia in hemodialysis patients: a prospective study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dyslipidemias; Female; Heptanoic Acids; Humans; Life Style; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cytoprotection; Drug Evaluation, Preclinical; Drug Synergism; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Male; Myocardium; Oxidative Stress; Pyrroles; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2014 |
Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyslipidemias; Endothelium, Vascular; Fatty Acids, Unsaturated; Heptanoic Acids; Male; Nitric Oxide; Pyrroles; Rabbits | 2014 |
The evolving role of CETP inhibition: beyond HDL cholesterol.
Topics: Cholesterol Ester Transfer Proteins; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Quinolines; Sulfonamides | 2015 |
Dyslipidaemia: Promising results for TA-8995 in TULIP.
Topics: Cholesterol Ester Transfer Proteins; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Quinolines; Sulfonamides | 2015 |
Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects?
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Hypoglycemic Agents; India; Marketing; Phenylpropionates; Pyrroles | 2015 |
Indian endocrinologists start debate on diabetes drug.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles | 2015 |
Reply: Intriguing Off-Target Effects of Ezetimibe.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Intriguing Off-Target Effects of Ezetimibe.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles | 2016 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles | 2016 |
Drug approvals in India - Authors' reply.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Marketing; Phenylpropionates; Pyrroles | 2016 |
Reply: Getting What the Guidelines Stated Matters.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Getting What the Guidelines Stated Matters.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Reply: Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: CHOICE Trial Results.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Reply: Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: CHOICE Trial Results.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.
Topics: Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Metabolic Syndrome; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2016 |
Lipid management: considerations in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Triglycerides | 2008 |
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.
Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Down-Regulation; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Pyrroles; Research Design; Treatment Outcome; Triglycerides | 2008 |
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult | 2008 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
An association study between catalase -262C>T gene polymorphism, sodium-lithium countertransport activity, insulin resistance, blood lipid parameters and their response to atorvastatin, in Greek dyslipidaemic patients and normolipidaemic controls.
Topics: Adult; Alleles; Antiporters; Atorvastatin; Case-Control Studies; Catalase; Dyslipidemias; Erythrocytes; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Linear Models; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies | 2009 |
Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Tacrolimus; Treatment Outcome; Triglycerides | 2009 |
Hypothyroidism misdiagnosed as statin intolerance.
Topics: Anticholesteremic Agents; Atorvastatin; Diagnostic Errors; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Male; Middle Aged; Myositis; Pyrroles | 2009 |
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2009 |
Lipid profile changes associated with changing available formulary statins: removing higher potency agents.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fasting; Formularies, Hospital as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Managed Care Programs; Medication Adherence; Pyrroles; Retrospective Studies; Triglycerides; United States | 2009 |
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Topics: Adolescent; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Atorvastatin; Biomarkers; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Puberty; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Research Design; Risk; Tetrahydroisoquinolines | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Atorvastatin-induced prolonged cholestasis with bile duct damage.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Cholestasis; Dyslipidemias; Heptanoic Acids; Humans; Male; Pyrroles; Ursodeoxycholic Acid | 2010 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Monitoring; Drug Synergism; Dyslipidemias; Heart Diseases; Heptanoic Acids; Humans; Hypertension; Patient Compliance; Pyrroles; Risk Factors | 2010 |
Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Primary Health Care; Proportional Hazards Models; Pyrroles; Risk Factors | 2011 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; Data Interpretation, Statistical; Dyslipidemias; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Hematocrit; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Time Factors | 2010 |
Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity.
Topics: Aged; Antioxidants; Atorvastatin; Ceruloplasmin; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidants; Pyrroles | 2010 |
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).
Topics: Aged; Atorvastatin; Canada; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prevalence; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Serum; Sulfonamides | 2011 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cricetinae; Disease Models, Animal; Dyslipidemias; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Malondialdehyde; Mesocricetus; Nitric Oxide; Phosphatidylcholine-Sterol O-Acyltransferase; Poloxamer; PPAR alpha; Pyrroles; RNA, Messenger; Superoxide Dismutase | 2011 |
Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans.
Topics: Algorithms; Atorvastatin; Cholesterol, LDL; Computer Simulation; Dose-Response Relationship, Drug; Drug Synergism; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Models, Biological; Phytosterols; Phytotherapy; Pyrroles | 2011 |
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
Topics: Adipocytes; Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; In Vitro Techniques; Intra-Abdominal Fat; Male; Middle Aged; Pyrroles; Subcutaneous Fat | 2011 |
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Topics: Adiponectin; Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Collagen Type IV; Dyslipidemias; Fatty Liver; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Regression Analysis; Severity of Illness Index; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles | 2011 |
Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism.
Topics: Atorvastatin; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Dyslipidemias; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Poland; Pyrroles; Treatment Outcome; Ultrasonography, Doppler, Color; Venous Thromboembolism | 2012 |
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Non-alcoholic Fatty Liver Disease; Pyrroles; Tumor Necrosis Factor-alpha | 2012 |
The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Lipid Peroxidation; Lipids; Male; Membrane Fluidity; Middle Aged; Oxidation-Reduction; Pyrroles; Sodium-Potassium-Exchanging ATPase | 2012 |
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Therapeutic Equivalency; Treatment Outcome; Triglycerides | 2013 |
Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides | 2012 |
[Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Comorbidity; Dyslipidemias; Erythrocytes; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Rheology; Severity of Illness Index | 2012 |
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Statins: is it safe and effective to use generic "equivalents"?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Drugs, Generic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2013 |
Impact of variants within seven candidate genes on statin treatment efficacy.
Topics: Aged; Alleles; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genetic Variation; Genome, Human; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2012 |
Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pilot Projects; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sex Factors; Simvastatin; Triglycerides | 2012 |
Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response.
Topics: Atherosclerosis; Atorvastatin; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2013 |
Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Europe; Female; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Physicians, Primary Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Risk; Secondary Care; Self Report; Simvastatin | 2013 |
[Atorvastatin and oxidative stress in coronary heart disease with obesity].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Case-Control Studies; Coronary Disease; Dyslipidemias; Electrocardiography, Ambulatory; Electron Spin Resonance Spectroscopy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Middle Aged; Obesity; Oxidative Stress; Pyrroles | 2012 |
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Podocytes; Pyrroles | 2013 |
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.
Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets | 2006 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.
Topics: Animals; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Quinolines | 2006 |
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Evaluation; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization.
Topics: Acyl Coenzyme A; Atorvastatin; Drug Costs; Dyslipidemias; Female; Formularies as Topic; Health Expenditures; Heptanoic Acids; Humans; Insurance Claim Review; Male; Managed Care Programs; Medicaid; Middle Aged; Pyrroles; Retrospective Studies; Therapeutic Equivalency | 2006 |
API expert consensus document on management of ischemic heart disease.
Topics: Angioplasty; Atorvastatin; Clinical Trials as Topic; Coronary Angiography; Drug Costs; Dyslipidemias; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Myocardial Infarction; Pyrroles; Streptokinase; Thrombolytic Therapy | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles | 2007 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2007 |
A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Simvastatin | 2007 |
The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2007 |
A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) s
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles | 2007 |